{"title":"HR ⩽10%/HER2阴性乳腺癌患者接受聚乙二醇脂质体多柔比星、表柔比星和吡拉比星新辅助化疗的反应和预后比较：一项探索性真实世界多中心队列研究。","authors":"Yue Hong, Jing Peng, Qitong Chen, Qin Zhou, Feng Xu, Jia Yao, Qiongyan Zou, Liqin Yuan, Lun Li, Qian Long, Liqiu Liao, Mingwen Liu, Xuan Liu, Danhua Zhang, Shouman Wang, Wenjun Yi","doi":"10.1177/17588359241279695","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pegylated liposomal doxorubicin (PLD), epirubicin and pirarubicin are the main anthracyclines widely used in China. PLD demonstrates therapeutic response comparable to epirubicin and pirarubicin in neoadjuvant chemotherapy (NAC) of breast cancer.</p><p><strong>Objectives: </strong>The objectives of our study were to retrospectively assess the real-world effectiveness and prognostic characteristics of PLD as NAC for HR ⩽ 10%/human epidermal growth factor receptor 2 (HER2)-negative breast cancer.</p><p><strong>Design: </strong>This was a retrospective study.</p><p><strong>Methods: </strong>Our study enrolled patients with HR ⩽ 10%/HER2-negative breast cancer who received PLD-, epirubicin- or pirarubicin-based NAC from three centres in Hunan Province, China, between 2015 and 2022. We employed inverse probability of treatment weighting to balance the differences in patients' characteristics among the PLD, epirubicin, and pirarubicin groups. The endpoints were pathological complete response (pCR), event-free survival (EFS), and overall survival (OS).</p><p><strong>Results: </strong>A total of 267 patients were included. After NAC, the pCR rates in PLD group were superior to epirubicin group (PLD, 34.1%; epirubicin, 20.8%, <i>p</i> = 0.038). The differences in EFS (log-rank <i>p</i> = 0.99) and OS (log-rank <i>p</i> = 0.33) among the three groups were not statistically significant. Among the three groups, non-pCR patients had worse EFS than pCR patients (log-rank <i>p</i> = 0.014). For patients with pCR, the differences in EFS (log-rank <i>p</i> = 0.47) and OS (log-rank <i>p</i> = 0.38) were not statistically significant among the three groups, and the EFS (log-rank <i>p</i> = 0.59) and OS (log-rank <i>p</i> = 0.14) of non-pCR patients in the PLD group were similar to those in the epirubicin and pirarubicin groups.</p><p><strong>Conclusion: </strong>PLD had a similar therapeutic response and prognosis compared to epirubicin or pirarubicin in NAC for patients with HR ⩽ 10%/HER2 negative breast cancer, which means that PLD represents a potential NAC option.</p>","PeriodicalId":23053,"journal":{"name":"Therapeutic Advances in Medical Oncology","volume":"16 ","pages":"17588359241279695"},"PeriodicalIF":4.3000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11428166/pdf/","citationCount":"0","resultStr":"{\"title\":\"Comparison of neoadjuvant chemotherapy response and prognosis among pegylated liposomal doxorubicin, epirubicin and pirarubicin in HR ⩽ 10%/HER2-negative breast cancer: an exploratory real-world multicentre cohort study.\",\"authors\":\"Yue Hong, Jing Peng, Qitong Chen, Qin Zhou, Feng Xu, Jia Yao, Qiongyan Zou, Liqin Yuan, Lun Li, Qian Long, Liqiu Liao, Mingwen Liu, Xuan Liu, Danhua Zhang, Shouman Wang, Wenjun Yi\",\"doi\":\"10.1177/17588359241279695\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Pegylated liposomal doxorubicin (PLD), epirubicin and pirarubicin are the main anthracyclines widely used in China. PLD demonstrates therapeutic response comparable to epirubicin and pirarubicin in neoadjuvant chemotherapy (NAC) of breast cancer.</p><p><strong>Objectives: </strong>The objectives of our study were to retrospectively assess the real-world effectiveness and prognostic characteristics of PLD as NAC for HR ⩽ 10%/human epidermal growth factor receptor 2 (HER2)-negative breast cancer.</p><p><strong>Design: </strong>This was a retrospective study.</p><p><strong>Methods: </strong>Our study enrolled patients with HR ⩽ 10%/HER2-negative breast cancer who received PLD-, epirubicin- or pirarubicin-based NAC from three centres in Hunan Province, China, between 2015 and 2022. We employed inverse probability of treatment weighting to balance the differences in patients' characteristics among the PLD, epirubicin, and pirarubicin groups. The endpoints were pathological complete response (pCR), event-free survival (EFS), and overall survival (OS).</p><p><strong>Results: </strong>A total of 267 patients were included. After NAC, the pCR rates in PLD group were superior to epirubicin group (PLD, 34.1%; epirubicin, 20.8%, <i>p</i> = 0.038). The differences in EFS (log-rank <i>p</i> = 0.99) and OS (log-rank <i>p</i> = 0.33) among the three groups were not statistically significant. Among the three groups, non-pCR patients had worse EFS than pCR patients (log-rank <i>p</i> = 0.014). For patients with pCR, the differences in EFS (log-rank <i>p</i> = 0.47) and OS (log-rank <i>p</i> = 0.38) were not statistically significant among the three groups, and the EFS (log-rank <i>p</i> = 0.59) and OS (log-rank <i>p</i> = 0.14) of non-pCR patients in the PLD group were similar to those in the epirubicin and pirarubicin groups.</p><p><strong>Conclusion: </strong>PLD had a similar therapeutic response and prognosis compared to epirubicin or pirarubicin in NAC for patients with HR ⩽ 10%/HER2 negative breast cancer, which means that PLD represents a potential NAC option.</p>\",\"PeriodicalId\":23053,\"journal\":{\"name\":\"Therapeutic Advances in Medical Oncology\",\"volume\":\"16 \",\"pages\":\"17588359241279695\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2024-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11428166/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Medical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/17588359241279695\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Medical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17588359241279695","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：聚乙二醇脂质体多柔比星（PLD）、表柔比星和吡拉比星是中国广泛使用的主要蒽环类药物。在乳腺癌新辅助化疗（NAC）中，PLD的治疗反应与表柔比星和吡柔比星相当：我们的研究旨在回顾性评估PLD作为HR⩽10%/人表皮生长因子受体2（HER2）阴性乳腺癌新辅助化疗的实际疗效和预后特征：这是一项回顾性研究：我们的研究纳入了中国湖南省三个中心在2015年至2022年间接受以PLD、表柔比星或吡拉比星为基础的新农合治疗的HR⩽10%/HER2阴性乳腺癌患者。我们采用了逆治疗概率加权法来平衡PLD组、表柔比星组和吡拉比星组之间患者特征的差异。研究终点为病理完全反应（pCR）、无事件生存期（EFS）和总生存期（OS）：结果：共纳入 267 例患者。NAC后，PLD组的病理完全反应率优于表柔比星组（PLD，34.1%；表柔比星，20.8%，P = 0.038）。三组患者的 EFS（log-rank p = 0.99）和 OS（log-rank p = 0.33）差异无统计学意义。在三组患者中，非 pCR 患者的 EFS 差于 pCR 患者（log-rank p = 0.014）。对于pCR患者，三组的EFS（log-rank p = 0.47）和OS（log-rank p = 0.38）差异无统计学意义，PLD组非CR患者的EFS（log-rank p = 0.59）和OS（log-rank p = 0.14）与表柔比星组和吡拉比星组相似：结论：对于HR⩽10%/HER2阴性乳腺癌患者，与表柔比星或吡拉比星相比，PLD在新农合中具有相似的治疗反应和预后，这意味着PLD是一种潜在的新农合选择。
Comparison of neoadjuvant chemotherapy response and prognosis among pegylated liposomal doxorubicin, epirubicin and pirarubicin in HR ⩽ 10%/HER2-negative breast cancer: an exploratory real-world multicentre cohort study.
Background: Pegylated liposomal doxorubicin (PLD), epirubicin and pirarubicin are the main anthracyclines widely used in China. PLD demonstrates therapeutic response comparable to epirubicin and pirarubicin in neoadjuvant chemotherapy (NAC) of breast cancer.
Objectives: The objectives of our study were to retrospectively assess the real-world effectiveness and prognostic characteristics of PLD as NAC for HR ⩽ 10%/human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
Design: This was a retrospective study.
Methods: Our study enrolled patients with HR ⩽ 10%/HER2-negative breast cancer who received PLD-, epirubicin- or pirarubicin-based NAC from three centres in Hunan Province, China, between 2015 and 2022. We employed inverse probability of treatment weighting to balance the differences in patients' characteristics among the PLD, epirubicin, and pirarubicin groups. The endpoints were pathological complete response (pCR), event-free survival (EFS), and overall survival (OS).
Results: A total of 267 patients were included. After NAC, the pCR rates in PLD group were superior to epirubicin group (PLD, 34.1%; epirubicin, 20.8%, p = 0.038). The differences in EFS (log-rank p = 0.99) and OS (log-rank p = 0.33) among the three groups were not statistically significant. Among the three groups, non-pCR patients had worse EFS than pCR patients (log-rank p = 0.014). For patients with pCR, the differences in EFS (log-rank p = 0.47) and OS (log-rank p = 0.38) were not statistically significant among the three groups, and the EFS (log-rank p = 0.59) and OS (log-rank p = 0.14) of non-pCR patients in the PLD group were similar to those in the epirubicin and pirarubicin groups.
Conclusion: PLD had a similar therapeutic response and prognosis compared to epirubicin or pirarubicin in NAC for patients with HR ⩽ 10%/HER2 negative breast cancer, which means that PLD represents a potential NAC option.
期刊介绍：
Therapeutic Advances in Medical Oncology is an open access, peer-reviewed journal delivering the highest quality articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in medical oncology, providing a forum in print and online for publishing the highest quality articles in this area. This journal is a member of the Committee on Publication Ethics (COPE).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
